Faye Coe
Faye Coe is an Advanced Clinical Oncology Pharmacist with a specialist interest in breast cancer based at St James’ hospital, Leeds Teaching Hosptial Trust, UK. She has worked in oncology for over 10 years with most of her oncology career based at Christie Hospital Foundation Trust, Manchester. Faye has published research on dose banding carboplatin and the effects on pathological complete response and on eribulin tolerability in breast cancer. She is a member of the British Oncology Pharmacy Association (BOPA) audit and research committee. Faye was the pharmacist advisor on the National Institute of Health and Care Excellence (UK) guideline for early and locally advanced breast cancer and remains a member of the expert advisor's panel.
Faye has been a Non-Medical Prescriber (NMP) since 2014 and has an extensive prescribing portfolio across various disease groups delivering pharmacist led clinics, consent clinics and prescribing all Systemic Anti-Cancer treatment across breast cancer clinics. She has a particular interest in the financial responsibilities within the National Health Service (NHS). She was part of the regional development and delivery of a bisphosphonate service for breast cancer patients in the North-West of England and has an ongoing interest in service development and improvement.
Abstracts this author is presenting: